CLCD - CoLucid Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.00
0.00 (0.00%)
At close: 7:00PM EST
Stock chart is not supported by your current browser
Previous CloseN/A
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Lilly Completes Acquisition of CoLucid Pharmaceuticals
    PR Newswirelast year

    Lilly Completes Acquisition of CoLucid Pharmaceuticals

    INDIANAPOLIS, March 1, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (CLCD). The tender offer for all outstanding shares of common stock of CoLucid, at a price of $46.50 per share, expired as scheduled on Tuesday, February 28, 2017. As of the expiration of the tender offer, 17,410,607 shares of CoLucid common stock were validly tendered, representing approximately 90.3 percent of the shares outstanding, and have been accepted for payment under the terms of the tender offer.

  • We're sorry this is all we were able to find about this topic.